|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...29303132333435363738394041» |
- Enrollment closed: Low Fat Diet and Multiple Sclerosis (clinicaltrials.gov) - Oct 28, 2012
P1, N=61, Active, not recruiting, Sponsor: Oregon Health and Science University
Recruiting --> Active, not recruiting
- ||||| RNS60 / Revalesio
New P2 trial: Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 23, 2012
P2, N=270, Not yet recruiting, Sponsor: Revalesio Corporation
- || everolimus / Generic mfg.
New P3 trial: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Oct 23, 2012
P3, N=355, Recruiting, Sponsor: Novartis Pharmaceuticals
- | Lemtrada (alemtuzumab) / Sanofi
New P1/2 trial: CAM-THY: Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis (clinicaltrials.gov) - Oct 22, 2012
P1/2, N=86, Recruiting, Sponsor: Cambridge University Hospitals NHS Foundation Trust
- | New P2 trial: Ginseng in Treatment of Fatigue in Multiple Sclerosis (clinicaltrials.gov) - Oct 21, 2012
P2, N=60, Completed, Sponsor: Isfahan University of Medical Sciences
- |||| Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Trial completion: DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine (clinicaltrials.gov) - Oct 18, 2012
P2, N=148, Completed, Sponsor: United Therapeutics
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Enrollment open: EARLiMS: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (clinicaltrials.gov) - Oct 17, 2012
P4, N=434, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- New P4 trial: Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS (clinicaltrials.gov) - Oct 16, 2012
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- ||| Betaseron (IFN-β-1b) / Bayer
Clinical: Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) (clinicaltrials.gov) - Oct 11, 2012
P=N/A, N=650, Recruiting, Sponsor: Bayer
- | Trial initiation date: RespiStimALS: Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation (clinicaltrials.gov) - Oct 11, 2012
P3, N=74, Recruiting, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting Initiation date: Jun 2012 --> Sep 2012
- ||| Tysabri (natalizumab) / Biogen
Clinical: COSTAN: Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (clinicaltrials.gov) - Oct 11, 2012
P=N/A, N=150, Recruiting, Sponsor: Biogen Idec
- | Enrollment open: RespiStimALS: Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation (clinicaltrials.gov) - Oct 11, 2012
P3, N=74, Recruiting, Sponsor: Assistance Publique - H
Initiation date: Jun 2012 --> Sep 2012 Not yet recruiting --> Recruiting
- Rebif (human IFN-β-1a) / EMD Serono
Trial completion: fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls (clinicaltrials.gov) - Oct 8, 2012
P4, N=21, Completed, Sponsor: Waukesha Memorial Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- Tysabri (natalizumab) / Biogen, Royalty, Betaseron (IFN-?-1b) / Bayer
New P4 trial: Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 3, 2012
P4, N=5, Terminated, Sponsor: Claudio Gobbi
- Enrollment open: WIRMS: Worms for Immune Regulation of Multiple Sclerosis (clinicaltrials.gov) - Oct 3, 2012
P2, N=72, Recruiting, Sponsor: University of Nottingham
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Rebif (human IFN-β-1a) / EMD Serono
Enrollment open: EMR200136-549: Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (clinicaltrials.gov) - Oct 1, 2012
P2, N=80, Recruiting, Sponsor: Merck KGaA
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: Mechanical Stress Effects on the Cardiovascular Adaptations of Peripheral Arterial Calcifications Among Athletes (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=90, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion, Review, Adherence: READER: An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=230, Completed, Sponsor: Merck KGaA
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Betaseron (IFN-?-1b) / Bayer
Enrollment change, Immunomodulating: Depression and Fatigue in MS Patients Treated With Betaferon. (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=252, Completed, Sponsor: Bayer
Active, not recruiting --> Completed N=400 --> 252
- ||| Betaseron (IFN-?-1b) / Bayer
Trial completion, Immunomodulating: Depression and Fatigue in MS Patients Treated With Betaferon. (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=252, Completed, Sponsor: Bayer
N=400 --> 252 Recruiting --> Completed
- ||| Trial completion: Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=103, Completed, Sponsor: Questcor Pharmaceuticals, Inc.
Recruiting --> Completed Recruiting --> Completed
- Enrollment change: A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia (clinicaltrials.gov) - Sep 24, 2012
P2, N=10, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed N=20 --> 10
- dactolisib (RTB101) / Adicet Bio
New P2 trial, Monotherapy, Metastases: A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa (clinicaltrials.gov) - Sep 20, 2012
P2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- ||||| Zinbryta (daclizumab) / Biogen, AbbVie
Enrollment closed: An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 19, 2012
P3, N=135, Active, not recruiting, Sponsor: Biogen Idec
N=20 --> 10 Recruiting --> Active, not recruiting
- trichuris suis ova (CNDO-201) / Fortress
Enrollment open: TRIOMS: Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome (clinicaltrials.gov) - Sep 13, 2012
P2, N=50, Recruiting, Sponsor: Charite University, Berlin, Germany
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enrollment closed: Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=2000, Active, not recruiting, Sponsor: Fondazione Italiana Sclerosi Multipla
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Avonex (recombinant IFN-β-1a) / Biogen
Enrollment closed, HEOR, Adherence: Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™. (clinicaltrials.gov) - Sep 12, 2012
P=N/A, N=280, Active, not recruiting, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Tcelna (imilecleucel-T) / Acer Therap, EMD Serono
New P2 trial: Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Sep 11, 2012
P2, N=180, Recruiting, Sponsor: Opexa Therapeutics, Inc.
- Clinical: Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis (clinicaltrials.gov) - Sep 11, 2012
P2, N=40, Completed, Sponsor: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial termination: Motor Training and White Matter in Multiple Sclerosis (MS) (clinicaltrials.gov) - Sep 10, 2012
P=N/A, N=60, Terminated, Sponsor: Hasselt University
Active, not recruiting --> Completed Recruiting --> Terminated
- || Rebif (human IFN-?-1a) / EMD Serono
Enrollment change, Adherence: SCANSMART: A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects (clinicaltrials.gov) - Sep 10, 2012
P=N/A, N=61, Completed, Sponsor: Merck KGaA
Recruiting --> Terminated N=100 --> 61
- ||| Rebif (human IFN-?-1a) / EMD Serono
Trial completion, Adherence: SCANSMART: A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects (clinicaltrials.gov) - Sep 10, 2012
P=N/A, N=61, Completed, Sponsor: Merck KGaA
N=100 --> 61 Recruiting --> Completed
- ||||| New P4 trial: Investigation of Sacroiliac Fusion Treatment (INSITE) (clinicaltrials.gov) - Sep 5, 2012
P4, N=200, Recruiting, Sponsor: SI-BONE, Inc.
- || Enrollment change: Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program (clinicaltrials.gov) - Sep 4, 2012
P=N/A, N=64, Completed, Sponsor: Novartis
Recruiting --> Completed N=1200 --> 64
- ||| Trial completion: Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program (clinicaltrials.gov) - Sep 4, 2012
P=N/A, N=64, Completed, Sponsor: Novartis
N=1200 --> 64 Enrolling by invitation --> Completed
- Trial completion: The Effect of Transcutaneous Electrical Nerve Stimulation (TENS) in Multiple Sclerosis (clinicaltrials.gov) - Sep 3, 2012
P=N/A, N=20, Completed, Sponsor: Hasselt University
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- |||| Extavia (IFN-β-1b) / Novartis
Trial completion: EPOC: A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Sep 3, 2012
P4, N=1053, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P2 trial: High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment (clinicaltrials.gov) - Sep 3, 2012
P2, N=1, Terminated, Sponsor: Seah Lim M.D.
- Trial termination, HEOR, Immunomodulating: The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients (clinicaltrials.gov) - Sep 1, 2012
P4, N=45, Terminated, Sponsor: Carmel Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Interim analysis showed that the odds for proving primary hypothesis are low.
- Enrollment change, HEOR, Immunomodulating: The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients (clinicaltrials.gov) - Sep 1, 2012
P4, N=45, Terminated, Sponsor: Carmel Medical Center
Active, not recruiting --> Terminated; Interim analysis showed that the odds for proving primary hypothesis are low. N=100 --> 45
- | memantine / Generic mfg.
Trial completion: Study on Cognitive Disorders of Multiple Sclerosis (clinicaltrials.gov) - Aug 30, 2012
P3, N=90, Completed, Sponsor: University Hospital, Caen
N=100 --> 45 Active, not recruiting --> Completed
- ||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: STRATIFY-1: JC-Virus (JCV) Antibody Program (clinicaltrials.gov) - Aug 29, 2012
P=N/A, N=1000, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: TIMER: A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients (clinicaltrials.gov) - Aug 29, 2012
P4, N=200, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion, Reflex: REFLEX: REbif FLEXible Dosing in Early Multiple Sclerosis (MS) (clinicaltrials.gov) - Aug 22, 2012
P3, N=517, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 21, 2012
P2, N=98, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: Nurse-Led Manualized Telephone Support Intervention (clinicaltrials.gov) - Aug 20, 2012
P=N/A, N=200, Recruiting, Sponsor: University of Dublin, Trinity College
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Trial initiation date, Surgery: BRAVE-DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis) (clinicaltrials.gov) - Aug 20, 2012
P3, N=679, Recruiting, Sponsor: S. Anna Hospital
Not yet recruiting --> Recruiting Initiation date: Jul 2011 --> Aug 2012
- | Enrollment open, Surgery: BRAVE-DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis) (clinicaltrials.gov) - Aug 20, 2012
P3, N=679, Recruiting, Sponsor: S. Anna Hospital
Initiation date: Jul 2011 --> Aug 2012 Not yet recruiting --> Recruiting
- || Enrollment change, HEOR: EMR200077-507: To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients (clinicaltrials.gov) - Aug 19, 2012
P=N/A, N=150, Completed, Sponsor: Merck KGaA
Not yet recruiting --> Recruiting N=240 --> 150
- Rebif (human IFN-β-1a) / EMD Serono
Enrollment closed: ReNew: Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (clinicaltrials.gov) - Aug 19, 2012
P=N/A, N=50, Active, not recruiting, Sponsor: Merck KGaA
N=240 --> 150 Recruiting --> Active, not recruiting